Literature DB >> 31883714

Transcatheter Self-Expandable Valve Implantation for Aortic Stenosis in Small Aortic Annuli: The TAVI-SMALL Registry.

Damiano Regazzoli1, Mauro Chiarito2, Francesco Cannata2, Matteo Pagnesi3, Mizuki Miura4, Francesca Ziviello5, Andrea Picci6, Jörg Reifart7, Federico De Marco8, Francesco Bedogni8, Marianna Adamo9, Salvatore Curello9, Rui Teles10, Maurizio Taramasso4, Marco Barbanti6, Corrado Tamburino6, Giulio G Stefanini2, Antonio Mangieri11, Francesco Giannini11, Paolo A Pagnotta12, Francesco Maisano4, Won-Keun Kim7, Nicolas M Van Mieghem5, Antonio Colombo11, Bernhard Reimers12, Azeem Latib13.   

Abstract

OBJECTIVES: The aim of this study was to evaluate and compare the outcomes of transcatheter self-expandable prostheses in patients with small annuli.
BACKGROUND: Transcatheter aortic heart valves appear to have better performance than surgical valves in terms of prosthesis-patient mismatch, especially in patients with aortic stenosis with small aortic annuli.
METHODS: TAVI-SMALL (International Multicenter Registry to Evaluate the Performance of Self-Expandable Valves in Small Aortic Annuli) is a retrospective registry of patients with severe aortic stenosis and small annuli (annular perimeter <72 mm or area <400 mm2 on computed tomography) treated with transcatheter self-expandable valves (n = 859; Evolut R, n = 397; Evolut PRO, n = 84; ACURATE, n = 201; Portico, n = 177). Primary endpoints were post-procedural mean aortic gradient, indexed effective orifice area, and rate of severe prosthesis-patient mismatch.
RESULTS: Pre-discharge gradients were consistently low in every group, with a slight benefit with the Evolut R (8.1 mm Hg; 95% confidence interval [CI]: 7.7 to 8.5 mm Hg) and Evolut PRO (6.9 mm Hg; 95% CI: 6.3 to 7.6 mm Hg) compared with the ACURATE (9.6 mm Hg; 95% CI: 8.9 to 10.2 mm Hg) and Portico (8.9 mm Hg; 95% CI: 8.2 to 9.6 mm Hg) groups (p < 0.001). Mean indexed effective orifice area was 1.04 cm2/m2 (95% CI: 1.01 to 1.08 cm2/m2) with a trend toward lower values with the Portico. No significant differences were reported in terms of severe prosthesis-patient mismatch (overall rate 9.4%; p = 0.134), permanent pacemaker implantation (15.6%), and periprocedural and 1-year adverse events. Pre-discharge more than mild paravalvular leaks were significantly more common with the Portico (19.2%) and less common with the Evolut PRO (3.6%) compared with the Evolut R (11.8%) and ACURATE (9%) groups.
CONCLUSIONS: Transcatheter self-expandable valves showed optimal clinical and echocardiographic results in patients with small aortic annuli, although supra-annular functioning transcatheter heart valves seemed to slightly outperform intra-annular functioning ones. The role of transcatheter aortic valve replacement with self-expandable valves for the treatment of aortic stenosis in patients with small annuli needs to be confirmed in larger trials.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TAVR; self-expandable valves; small annuli

Mesh:

Year:  2019        PMID: 31883714     DOI: 10.1016/j.jcin.2019.08.041

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  8 in total

Review 1.  Prosthesis-patient mismatch after transcatheter aortic valve implantation.

Authors:  Masaki Miyasaka
Journal:  Cardiovasc Interv Ther       Date:  2022-06-16

2.  10-Year Impact of Transcatheter Aortic Valve Replacement Leaflet Design (Intra- Versus Supra-Annular) in Mortality and Hemodynamic Performance.

Authors:  Andrea Scotti; Luca Nai Fovino; Augustin Coisne; Tommaso Fabris; Francesco Cardaioli; Mauro Massussi; Giulio Rodinò; Alberto Barolo; Mauro Boiago; Saverio Continisio; Carolina Montonati; Tommaso Sciarretta; Vittorio Zuccarelli; Valentina Bernardini; Giulia Masiero; Massimo Napodano; Chiara Fraccaro; Alfredo Marchese; Giovanni Esposito; Juan F Granada; Azeem Latib; Sabino Iliceto; Giuseppe Tarantini
Journal:  Front Cardiovasc Med       Date:  2022-06-08

3.  Coronary Angiography After Transcatheter Aortic Valve Replacement (TAVR) to Evaluate the Risk of Coronary Access Impairment After TAVR-in-TAVR.

Authors:  Luca Nai Fovino; Andrea Scotti; Mauro Massussi; Francesco Cardaioli; Giulio Rodinò; Yuji Matsuda; Andrea Pavei; Giulia Masiero; Massimo Napodano; Chiara Fraccaro; Tommaso Fabris; Giuseppe Tarantini
Journal:  J Am Heart Assoc       Date:  2020-06-24       Impact factor: 5.501

4.  Patient Prosthesis Mismatch After SAVR and TAVR.

Authors:  Sabine Bleiziffer; Tanja K Rudolph
Journal:  Front Cardiovasc Med       Date:  2022-03-30

Review 5.  Evolving Devices and Material in Transcatheter Aortic Valve Replacement: What to Use and for Whom.

Authors:  Mauro Chiarito; Alessandro Spirito; Johny Nicolas; Alexandra Selberg; Giulio Stefanini; Antonio Colombo; Bernhard Reimers; Annapoorna Kini; Samin K Sharma; George D Dangas; Roxana Mehran
Journal:  J Clin Med       Date:  2022-07-30       Impact factor: 4.964

Review 6.  Technical Aspects and Development of Transcatheter Aortic Valve Implantation.

Authors:  Klemen Steblovnik; Matjaz Bunc
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-22

Review 7.  Clinical and Technical Challenges of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Implantation.

Authors:  Pier Pasquale Leone; Fabio Fazzari; Francesco Cannata; Jorge Sanz-Sanchez; Antonio Mangieri; Lorenzo Monti; Ottavia Cozzi; Giulio Giuseppe Stefanini; Renato Bragato; Antonio Colombo; Bernhard Reimers; Damiano Regazzoli
Journal:  Front Cardiovasc Med       Date:  2021-06-04

8.  Transcatheter aortic valve implantation in patients with a small aortic annulus: performance of supra-, intra- and infra-annular transcatheter heart valves.

Authors:  Lisa Voigtländer; Won-Keun Kim; Victor Mauri; Alina Goßling; Matthias Renker; Atsushi Sugiura; Matthias Linder; Tobias Schmidt; Niklas Schofer; Dirk Westermann; Hermann Reichenspurner; Georg Nickenig; Stefan Blankenberg; Christian Hamm; Lenard Conradi; Matti Adam; Jan-Malte Sinning; Moritz Seiffert
Journal:  Clin Res Cardiol       Date:  2021-08-13       Impact factor: 5.460

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.